Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1 - Archive ouverte HAL Access content directly
Journal Articles Nature Communications Year : 2018

Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1

(1) , (2, 3) , (4, 5) , (6, 7) , (1) , (5, 4) , (8) , (1) , (4, 5) , (3) , (9) , (10) , (2) , (3, 7) , (3, 7) , (11) , (8) , (2, 3) , (1)
1
2
3
4
5
6
7
8
9
10
11

Abstract

Genetic, epigenetic, and environmental factors contribute to the multifactorial disorder progressive supranuclear palsy (PSP). Here, we study epigenetic changes by genome-wide analysis of DNA from postmortem tissue of forebrains of patients and controls and detect significant (P < 0.05) methylation differences at 717 CpG sites in PSP vs. controls. Four-hundred fifty-one of these sites are associated with protein-coding genes. While differential methylation only affects a few sites in most genes, DLX1 is hypermethylated at multiple sites. Expression of an antisense transcript of DLX1, DLX1AS, is reduced in PSP brains. The amount of DLX1 protein is increased in gray matter of PSP forebrains. Pathway analysis suggests that DLX1 influences MAPT-encoded Tau protein. In a cell system, overexpression of DLX1 results in downregulation of MAPT while overexpression of DLX1AS causes upregulation of MAPT. Our observations suggest that altered DLX1 methylation and expression contribute to pathogenesis of PSP by influencing MAPT

Dates and versions

cea-01877684 , version 1 (20-09-2018)

Identifiers

Cite

Axel Weber, Sigrid C. Schwarz, Jorg Tost, Dietrich Trümbach, Pia Winter, et al.. Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1. Nature Communications, 2018, 9, pp.2929. ⟨10.1038/s41467-018-05325-y⟩. ⟨cea-01877684⟩
170 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More